NCT05159388View on ClinicalTrials.gov

A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 8, 2021

Primary Completion Date

April 8, 2025

Study Completion Date

April 8, 2025

Conditions

Solid Tumor

Interventions

DRUG

PRS-344/S095012

PRS-344/S095012 Monotherapy

Trial Locations (11)

28050

START, Madrid

28078

Carolina Bio Oncology, Huntersville

78229

NEXT Oncology, San Antonio

Unknown

Cabrini Oncology Research, Malvern

Chris O'Brian Lifehouse, Camperdown

The Queen Elizabeth Hospital, Woodville South

Institute Jules Bordet, Brussels

Universitair Ziekenhuis, Edegem

U.Z. Gent Medical Oncology, Ghent

Hospital Vall d'Hebron, Barcelona

Hospital Universitario Gregorio, Madrid

All Listed Sponsors

collaborator

Institut de Recherches Internationales Servier

OTHER

lead

Servier Bio-Innovation LLC

INDUSTRY

NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter